Warby Parker [WRBY] vs Repligen [RGEN] Detailed Stock Comparison
Warby Parker
NYSE
Loading...
Repligen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Warby Parker wins in 8 metrics, Repligen wins in 10 metrics, with 0 ties. Repligen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Warby Parker | Repligen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -156.24 | 511.11 | Warby Parker |
| Price-to-Book Ratio | 8.83 | 3.42 | Repligen |
| Debt-to-Equity Ratio | 63.18 | 33.28 | Repligen |
| PEG Ratio | 1.87 | 3.19 | Warby Parker |
| EV/EBITDA | 97.75 | 55.02 | Repligen |
| Profit Margin (TTM) | -1.12% | -2.05% | Warby Parker |
| Operating Margin (TTM) | -2.03% | 5.28% | Repligen |
| EBITDA Margin (TTM) | N/A | 5.28% | N/A |
| Return on Equity | -2.67% | -0.68% | Repligen |
| Return on Assets (TTM) | -1.56% | 1.13% | Repligen |
| Free Cash Flow (TTM) | $34.71M | $142.49M | Repligen |
| 1-Year Return | 74.73% | -14.99% | Warby Parker |
| Price-to-Sales Ratio (TTM) | 3.89 | 10.45 | Warby Parker |
| Enterprise Value | $3.16B | $6.96B | Repligen |
| EV/Revenue Ratio | 3.85 | 10.32 | Warby Parker |
| Gross Profit Margin (TTM) | 52.97% | 49.98% | Warby Parker |
| Revenue per Share (TTM) | $7 | $12 | Repligen |
| Earnings per Share (Diluted) | $-0.08 | $-0.25 | Warby Parker |
| Beta (Stock Volatility) | 2.10 | 1.05 | Repligen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Warby Parker vs Repligen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Warby Parker | 3.68% | -0.37% | 9.97% | 34.01% | 16.21% | 6.63% |
| Repligen | 4.30% | 0.35% | 9.35% | 3.60% | -24.25% | -12.76% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Warby Parker | 74.73% | 102.09% | -51.43% | -51.43% | -51.43% | -51.43% |
| Repligen | -14.99% | -45.06% | -16.91% | 263.93% | 3,581.12% | 3,356.79% |
Performance & Financial Health Analysis: Warby Parker vs Repligen
| Metric | WRBY | RGEN |
|---|---|---|
| Market Information | ||
| Market Cap | $3.19B | $7.04B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2,133,839 | 689,361 |
| 90 Day Avg. Volume | 1,748,296 | 907,097 |
| Last Close | $27.03 | $124.79 |
| 52 Week Range | $12.69 - $29.73 | $102.97 - $182.52 |
| % from 52W High | -9.08% | -31.63% |
| All-Time High | $60.30 (Nov 08, 2021) | $327.32 (Sep 20, 2021) |
| % from All-Time High | -55.17% | -61.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.15% |
| Quarterly Earnings Growth | 0.14% | 1.60% |
| Financial Health | ||
| Profit Margin (TTM) | -0.01% | -0.02% |
| Operating Margin (TTM) | -0.02% | 0.05% |
| Return on Equity (TTM) | -0.03% | -0.01% |
| Debt to Equity (MRQ) | 63.18 | 33.28 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.96 | $36.65 |
| Cash per Share (MRQ) | $2.35 | $12.60 |
| Operating Cash Flow (TTM) | $116.75M | $132.11M |
| Levered Free Cash Flow (TTM) | $44.33M | $155.35M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Warby Parker vs Repligen
| Metric | WRBY | RGEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -156.24 | 511.11 |
| Forward P/E | 81.81 | 70.34 |
| PEG Ratio | 1.87 | 3.19 |
| Price to Sales (TTM) | 3.89 | 10.45 |
| Price to Book (MRQ) | 8.83 | 3.42 |
| Market Capitalization | ||
| Market Capitalization | $3.19B | $7.04B |
| Enterprise Value | $3.16B | $6.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.85 | 10.32 |
| Enterprise to EBITDA | 97.75 | 55.02 |
| Risk & Other Metrics | ||
| Beta | 2.10 | 1.05 |
| Book Value per Share (MRQ) | $2.96 | $36.65 |
Financial Statements Comparison: Warby Parker vs Repligen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | WRBY | RGEN |
|---|---|---|
| Revenue/Sales | $223.78M | $182.37M |
| Cost of Goods Sold | $97.80M | $91.22M |
| Gross Profit | $125.98M | $91.14M |
| Research & Development | N/A | $13.96M |
| Operating Income (EBIT) | $2.47M | $5.96M |
| EBITDA | $14.63M | $33.81M |
| Pre-Tax Income | $4.93M | $18.22M |
| Income Tax | $1.45M | $3.35M |
| Net Income (Profit) | $3.47M | $14.87M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | WRBY | RGEN |
|---|---|---|
| Cash & Equivalents | $265.07M | $697.23M |
| Total Current Assets | $330.60M | $1.03B |
| Total Current Liabilities | $122.61M | $152.00M |
| Long-Term Debt | $204.78M | $668.54M |
| Total Shareholders Equity | $354.09M | $1.99B |
| Retained Earnings | $-683.75M | $413.18M |
| Property, Plant & Equipment | $170.19M | $265.24M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | WRBY | RGEN |
|---|---|---|
| Operating Cash Flow | $27.67M | $14.16M |
| Capital Expenditures | $-16.15M | $-3.52M |
| Free Cash Flow | $13.21M | $10.58M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | WRBY | RGEN |
|---|---|---|
| Shares Short | 9.08M | 3.64M |
| Short Ratio | 5.77 | 3.98 |
| Short % of Float | 0.09% | 0.09% |
| Average Daily Volume (10 Day) | 2,133,839 | 689,361 |
| Average Daily Volume (90 Day) | 1,748,296 | 907,097 |
| Shares Outstanding | 120.85M | 56.09M |
| Float Shares | 88.16M | 52.66M |
| % Held by Insiders | 0.07% | 0.06% |
| % Held by Institutions | 0.96% | 1.06% |
Dividend Analysis & Yield Comparison: Warby Parker vs Repligen
| Metric | WRBY | RGEN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |